Our Pipeline

We are cultivating a differentiated pipeline of small molecule medicines that utilize first-in-class or potential best-in-class mechanisms of action (MoAs) to reduce the neuronal hyperexcitability that underlies debilitating brain conditions including epilepsy. Our unique understanding of the complexities of neurologic systems allows us to turn preclinical potential into clinical meaning.

Our aim is to make a meaningful impact and address the significant unmet need in the lives of individuals with epilepsies and neurological disorders that present with brain conditions.